PMVP – pmv pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
Form 10-Q PMV Pharmaceuticals, For: Sep 30
Form 8-K PMV Pharmaceuticals, For: Nov 12
Form SCHEDULE 13G/A PMV Pharmaceuticals, Filed by: Sio Capital Management, LLC
Form 4 PMV Pharmaceuticals, For: Oct 27 Filed by: Mack David Henry
Form 4 PMV Pharmaceuticals, For: Oct 23 Filed by: ORBIMED ADVISORS LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.